Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial of Crizanlizumab for the Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)

NCT04611880 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT04611880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04611880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial of Crizanlizumab for the Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Completed
Start date
January 25, 2021
Completion date
December 31, 2025
Enrollment
18 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rvcl - retinal vasculopathy cerebral leukoencephalopathy